RT Journal Article
SR Electronic
T1 Evaluating Clinical Presentation and Long-Term Outcomes in Individuals with Genetic and Non-Genetic Epilepsy Treated with Epilepsy Surgery: A Single-Center Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.03.23299306
DO 10.1101/2023.12.03.23299306
A1 Ivaniuk, Alina
A1 Boßelmann, Christian M
A1 Pestana-Knight, Elia
A1 Zhang, Xiaoming
A1 Jehi, Lara
A1 Bingaman, William
A1 Najm, Imad
A1 Lal, Dennis
YR 2023
UL http://medrxiv.org/content/early/2023/12/04/2023.12.03.23299306.abstract
AB Background Many genetic epilepsy disorders are characterized by focal epilepsy or exhibit focal or lateralized features, which make individuals with such conditions potential surgical candidates. However, surgical outcomes in epilepsy caused by germline genetic variants and value of genetic testing in presurgical assessment remains unclear.Methods This retrospective cross-sectional study included people with germline genetic epilepsy and non-genetic epilepsy identified among 2879 people with epilepsy who underwent resective surgery or laser ablation at Cleveland Clinic in years 1997-2022. We separated individuals with germline genetic epilepsies into mTORopathies (clinically or genetically diagnosed tuberous sclerosis and genetically diagnosed GATOR-related epilepsies) and other genetic etiologies. We compared clinical variables between the groups using Kruskal-Wallis and Fisher tests as appropriate. We analyzed cumulative seizure recurrence risk over 5 years with Kaplan-Meier curves and used Cox proportional hazards model for univariate and multivariate analysis. We repeated the analysis after matching both genetic sub-groups to non-genetic group 1:1 by propensity scores estimated by a generalized linear model.Results We included 49 individuals with genetic epilepsies (32 individuals with mTORopathies and 17 individuals with other genetic etiologies) and 585 individuals with non-genetic epilepsy. Individuals with genetic epilepsies in both groups were younger at seizure onset (p<0.001) and at surgery (p<0.001), had a higher preoperative seizure frequency (p<0.001), higher rate of developmental delay (p<0.001), lower rate of focal interictal (p=0.005) and ictal (p<0.001) findings on EEG, and more extratemporal and extensive resections (p<0.001). At the last follow-up, individuals with other genetic etiologies had a lower rate of seizure freedom than individuals with mTORopathies and non-genetic etiologies; still, 70.6% achieved seizure reduction. Individuals with other genetic etiologies had a higher cumulative risk of seizure recurrence at 5 years both in univariate (HR 3.07, 95% CI 1.4-6.74) and multivariate (HR 3.81, 95% CI 1.69-8.62, p=0.001) analyses, which was reproducible in a matched cohort analysis.Conclusions People with germline genetic epilepsy across multiple etiologies could be surgical candidates. However, seizure recurrence may be faster in genetic epilepsies other than mTORopathies. Further studies are required to clarify surgical candidacy in different genetic epilepsy disorders and establish value of presurgical genetic testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Cleveland Clinic Institutional Review Board as a consent-exempt study (protocol identifiers 23-251 and 17-1015).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.